Ted W. Simon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ted W. Simon has a total of 153 co-authors. Here are the top co-authors by number of shared publications:
J. Craig Rowlands
The Dow Chemical Company, Toxicology and Environmental Research & Consulting. Midland, MI, United States of America
6 shared publicationsRobert A. Budinsky
The Dow Chemical Company, Midland, MI, USA [retired
5 shared publications- Lesa L. Aylward
Summit Toxicology, LLP, Falls Church, VA 22044, USA
3 shared publications Richard A. Becker
Long Range Research Initiative, Senior Toxicologist, American Chemistry Council, Inc, Washington, District of Columbia
3 shared publicationsChristopher R. Kirman
‡ The Sapphire Group, Beachwood, Ohio 44122
2 shared publications- Ronald L. Calabrese
Biology Department, Emory University, Atlanta, GA, 30322
2 shared publications
Latest Publications
- Open Access
- 14 July 2026
- Published by Forschungsgesellschaft für Arbeitsphysiologie und Arbeitsschutz e.V. in EXCLI Journal
- Vol. 25, 1107-1116
Retraction of the landmark glyphosate safety publication by Williams, Kroes and Munro (2000) should be reversed
The decision by the co-Editor-in-Chief of Regulatory Toxicology and Pharmacology, Prof. Martin van den Berg, to retract the 2000 review article by Williams, Kroes, and Munro has elicited widespread criticism within the scientific community. Issued in late 2025, the retraction decision cites procedural concerns including potential ghostwriting, undisclosed conflicts of interest, and omission of certain unpublished studies, invoking Committee on Publication Ethics guidelines despite lacking evidence of fraud or scientific flaws. This editorial argues that the retraction decision involves editorial overreach and misapplication of the guidelines. The alleged omissions stemmed from proprietary data access limitations that were disclosed in the original paper. Subsequent reviews by several independent expert panels and regulatory authorities with access to all glyphosate data, including the studies cited by the retracting editor, reached similar conclusions. Claims of ghostwriting were previously investigated and found lacking, including a declaration by EFSA as to the clarity of the conflict disclosures. The retraction’s timing, reliance on litigation documents, and apparent biases that were not disclosed in the retraction notice raise questions of ideological interference. Absent substantive rebuttals based on scientific merit rather than speculative claims of inappropriate authorship and data access, this retraction decision sets a dangerous precedent for retroactive censorship, potentially chilling beneficial industry-academic collaborations and eroding trust in the integrity of scientific publishing. With the strongest conviction, we assert that retracting a paper without scientific flaws isn’t protection—it is censorship. We therefore call for the immediate reversal of this flawed and unjustified retraction to preserve trust in peer-reviewed literature.
- 14 July 2026
- Published by Forschungsgesellschaft für Arbeitsphysiologie und Arbeitsschutz e.V. in EXCLI Journal
- Vol. 25, 1107-1116
Open AccessRetraction of the landmark glyphosate safety publication by Williams, Kroes and Munro (2000) should be reversed
The decision by the co-Editor-in-Chief of Regulatory Toxicology and Pharmacology, Prof. Martin van den Berg, to retract the 2000 review article by Williams, Kroes, and Munro has elicited widespread criticism within the scientific community. Issued in late 2025, the retraction decision cites procedural concerns including potential ghostwriting, undisclosed conflicts of interest, and omission of certain unpublished studies, invoking Committee on Publication Ethics guidelines despite lacking evidence of fraud or scientific flaws. This editorial argues that the retraction decision involves editorial overreach and misapplication of the guidelines. The alleged omissions stemmed from proprietary data access limitations that were disclosed in the original paper. Subsequent reviews by several independent expert panels and regulatory authorities with access to all glyphosate data, including the studies cited by the retracting editor, reached similar conclusions. Claims of ghostwriting were previously investigated and found lacking, including a declaration by EFSA as to the clarity of the conflict disclosures. The retraction’s timing, reliance on litigation documents, and apparent biases that were not disclosed in the retraction notice raise questions of ideological interference. Absent substantive rebuttals based on scientific merit rather than speculative claims of inappropriate authorship and data access, this retraction decision sets a dangerous precedent for retroactive censorship, potentially chilling beneficial industry-academic collaborations and eroding trust in the integrity of scientific publishing. With the strongest conviction, we assert that retracting a paper without scientific flaws isn’t protection—it is censorship. We therefore call for the immediate reversal of this flawed and unjustified retraction to preserve trust in peer-reviewed literature.
- 6 February 2025
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 408, 111414
Calibration and evaluation of a refined pharmacokinetic model for three homologs of phosphatidylethanol
- 6 February 2025
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 408, 111414
Calibration and evaluation of a refined pharmacokinetic model for three homologs of phosphatidylethanol
- 1 January 2025
- Published by International Society of Regulatory Toxicology and Pharmacology in Journal of Toxicology and Regulatory Policy
- Vol. 1 (1) , 1-7
Incorporation of the concept of tipping points into adverse outcome pathways (AOPs)
SUMMARY: The concept of the adverse outcome pathway (AOP) has evolved since inception. Recent advances include a variety of methods for developing quantitative AOPs (qAOPs). The goal is prediction of adverse outcomes from a range of stressors that activate molecular initiating events (MIEs) that in turn trigger a sequence of key events (KEs) leading ultimately to the adverse outcome (AO). Inherent in qAOPs is the implicit assumption of probabilities of transition along this sequence of key event relationships (KERs) based on the degree of activation of the MIE and each subsequent KE. These probabilities are the basis of the KER tipping points and are a function of not only the dysregulation induced by the stressor but also adaptation or resilience of the organism to counter this dysregulation. Two groups of qAOPs are considered here. The first group relies on data and systems biology modeling, an effort dependent on data at all levels of organization including molecules, cells, tissue, organs, organisms, and populations. The second group use methods that are much less data-dependent and are based on certain types of Bayesian networks (BNs). The difficulty with reconciling the biology inherent in the AOP concept with a purely statistical technique such as BNs is the presence of feedback control loops in biological systems that are inconsistent with the one-way information flow permitted in BNs. However, recent developments in BNs may permit such feedback loops. Here we envision a prediction model for qAOPs that depends on newer types of BNs along with a time-dynamic model to estimate the probabilities of exceeding tipping points. Such a model has not yet been developed, but several qAOPs developed with BNs seem ripe for testing this model.
- 1 January 2025
- Published by International Society of Regulatory Toxicology and Pharmacology in Journal of Toxicology and Regulatory Policy
- Vol. 1 (1) , 1-7
Incorporation of the concept of tipping points into adverse outcome pathways (AOPs)
SUMMARY: The concept of the adverse outcome pathway (AOP) has evolved since inception. Recent advances include a variety of methods for developing quantitative AOPs (qAOPs). The goal is prediction of adverse outcomes from a range of stressors that activate molecular initiating events (MIEs) that in turn trigger a sequence of key events (KEs) leading ultimately to the adverse outcome (AO). Inherent in qAOPs is the implicit assumption of probabilities of transition along this sequence of key event relationships (KERs) based on the degree of activation of the MIE and each subsequent KE. These probabilities are the basis of the KER tipping points and are a function of not only the dysregulation induced by the stressor but also adaptation or resilience of the organism to counter this dysregulation. Two groups of qAOPs are considered here. The first group relies on data and systems biology modeling, an effort dependent on data at all levels of organization including molecules, cells, tissue, organs, organisms, and populations. The second group use methods that are much less data-dependent and are based on certain types of Bayesian networks (BNs). The difficulty with reconciling the biology inherent in the AOP concept with a purely statistical technique such as BNs is the presence of feedback control loops in biological systems that are inconsistent with the one-way information flow permitted in BNs. However, recent developments in BNs may permit such feedback loops. Here we envision a prediction model for qAOPs that depends on newer types of BNs along with a time-dynamic model to estimate the probabilities of exceeding tipping points. Such a model has not yet been developed, but several qAOPs developed with BNs seem ripe for testing this model.
- 28 March 2024
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 149, 105594
Commentary: Value of information case study strongly supports use of the Threshold of Toxicological Concern (TTC)
- 28 March 2024
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 149, 105594
Commentary: Value of information case study strongly supports use of the Threshold of Toxicological Concern (TTC)
- 8 October 2021
- Published by Taylor & Francis
- p. 235-266
Cannabis Pharmacokinetics and Pharmacodynamics
This chapter provides a summary, as of late 2020, of the state of knowledge of cannabis pharmacokinetics and pharmacodynamics. First, the absorption, distribution, metabolism, and elimination of both THC and CBD are described. Then follows a summary of the existing pharmacokinetic models for both substances. The section ends with the presentation of a new model for THC that includes the elimination of both carboxy-THC and its glucuronide conjugate. Many endogenous and exogenous substances are conjugated with glucuronic acid, a highly polar moiety, to enhance both biliary and urinary excretion. Humans have a high capacity for glucuronidation to foster the elimination of bilirubin, the toxic by-product of hemoglobin degradation and the cause of jaundice, a yellowing of the skin and eyes in those with compromised liver function. The chapter continues with a review of the endocannabinoid system. Endocannabinoids are molecules produced within the body that bind to cannabinoid receptors. The two primary endocannabinoids are 2-arachidonoylglycerol and anandamide. The function of these molecules and the associated receptors is to modulate synaptic transmission at GABAergic and glutamatergic synapses. THC acts at the CB1 receptor and CBD acts at the CB2 receptor. The endocannabinoid system itself likely includes other components and the understanding of this system’s normal functioning is still developing. The chapter concludes with three examples of cannabinoid effects: the impairing effect of THC on driving ability by modulation of attention; the effect of THC on the heart and the relation to sudden heart attacks; and the reduction of anxiety brought on by the use of CBD. The glimpse of cannabis science presented here will likely be supplanted as continuing interest in both endogenous and exogenous cannabinoids is driving additional research.
- 8 October 2021
- Published by Taylor & Francis
- p. 235-266
Cannabis Pharmacokinetics and Pharmacodynamics
This chapter provides a summary, as of late 2020, of the state of knowledge of cannabis pharmacokinetics and pharmacodynamics. First, the absorption, distribution, metabolism, and elimination of both THC and CBD are described. Then follows a summary of the existing pharmacokinetic models for both substances. The section ends with the presentation of a new model for THC that includes the elimination of both carboxy-THC and its glucuronide conjugate. Many endogenous and exogenous substances are conjugated with glucuronic acid, a highly polar moiety, to enhance both biliary and urinary excretion. Humans have a high capacity for glucuronidation to foster the elimination of bilirubin, the toxic by-product of hemoglobin degradation and the cause of jaundice, a yellowing of the skin and eyes in those with compromised liver function. The chapter continues with a review of the endocannabinoid system. Endocannabinoids are molecules produced within the body that bind to cannabinoid receptors. The two primary endocannabinoids are 2-arachidonoylglycerol and anandamide. The function of these molecules and the associated receptors is to modulate synaptic transmission at GABAergic and glutamatergic synapses. THC acts at the CB1 receptor and CBD acts at the CB2 receptor. The endocannabinoid system itself likely includes other components and the understanding of this system’s normal functioning is still developing. The chapter concludes with three examples of cannabinoid effects: the impairing effect of THC on driving ability by modulation of attention; the effect of THC on the heart and the relation to sudden heart attacks; and the reduction of anxiety brought on by the use of CBD. The glimpse of cannabis science presented here will likely be supplanted as continuing interest in both endogenous and exogenous cannabinoids is driving additional research.
- 1 April 2018
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 94, 163-171
Providing context for phosphatidylethanol as a biomarker of alcohol consumption with a pharmacokinetic model
- 1 April 2018
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 94, 163-171
Providing context for phosphatidylethanol as a biomarker of alcohol consumption with a pharmacokinetic model
- Top Cited Papers
- 1 March 2018
- Published by Elsevier in Toxicology in Vitro
- Vol. 47, 213-227
In vitro to in vivo extrapolation for high throughput prioritization and decision making
- 1 March 2018
- Published by Elsevier in Toxicology in Vitro
- Vol. 47, 213-227
Top Cited PapersIn vitro to in vivo extrapolation for high throughput prioritization and decision making
- Open Access
- 1 October 2016
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 80, 9-24
Bayesian methods for uncertainty factor application for derivation of reference values
- 1 October 2016
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 80, 9-24
Open AccessBayesian methods for uncertainty factor application for derivation of reference values
- Open Access
- 1 April 2016
- Published by Elsevier in Environment International
- Vol. 89-90, 110-128
Approaches for describing and communicating overall uncertainty in toxicity characterizations: U.S. Environmental Protection Agency's Integrated Risk Information System (IRIS) as a case study
- 1 April 2016
- Published by Elsevier in Environment International
- Vol. 89-90, 110-128
Open AccessApproaches for describing and communicating overall uncertainty in toxicity characterizations: U.S. Environmental Protection Agency's Integrated Risk Information System (IRIS) as a case study
- Open Access
- 3 June 2015
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (6) , e0127952
A Model for Aryl Hydrocarbon Receptor-Activated Gene Expression Shows Potency and Efficacy Changes and Predicts Squelching Due to Competition for Transcription Co-Activators
A stochastic model of nuclear receptor-mediated transcription was developed based on activation of the aryl hydrocarbon receptor (AHR) by 2,3,7,8-tetrachlorodibenzodioxin (TCDD) and subsequent binding the activated AHR to xenobiotic response elements (XREs) on DNA. The model was based on effects observed in cells lines commonly used as in vitro experimental systems. Following ligand binding, the AHR moves into the cell nucleus and forms a heterodimer with the aryl hydrocarbon nuclear translocator (ARNT). In the model, a requirement for binding to DNA is that a generic coregulatory protein is subsequently bound to the AHR-ARNT dimer. Varying the amount of coregulator available within the nucleus altered both the potency and efficacy of TCDD for inducing for transcription of CYP1A1 mRNA, a commonly used marker for activation of the AHR. Lowering the amount of available cofactor slightly increased the EC50 for the transcriptional response without changing the efficacy or maximal response. Further reduction in the amount of cofactor reduced the efficacy and produced non-monotonic dose-response curves (NMDRCs) at higher ligand concentrations. The shapes of these NMDRCs were reminiscent of the phenomenon of squelching. Resource limitations for transcriptional machinery are becoming apparent in eukaryotic cells. Within single cells, nuclear receptor-mediated gene expression appears to be a stochastic process; however, intercellular communication and other aspects of tissue coordination may represent a compensatory process to maintain an organism’s ability to respond on a phenotypic level to various stimuli within an inconstant environment.
- 3 June 2015
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (6) , e0127952
Open AccessA Model for Aryl Hydrocarbon Receptor-Activated Gene Expression Shows Potency and Efficacy Changes and Predicts Squelching Due to Competition for Transcription Co-Activators
A stochastic model of nuclear receptor-mediated transcription was developed based on activation of the aryl hydrocarbon receptor (AHR) by 2,3,7,8-tetrachlorodibenzodioxin (TCDD) and subsequent binding the activated AHR to xenobiotic response elements (XREs) on DNA. The model was based on effects observed in cells lines commonly used as in vitro experimental systems. Following ligand binding, the AHR moves into the cell nucleus and forms a heterodimer with the aryl hydrocarbon nuclear translocator (ARNT). In the model, a requirement for binding to DNA is that a generic coregulatory protein is subsequently bound to the AHR-ARNT dimer. Varying the amount of coregulator available within the nucleus altered both the potency and efficacy of TCDD for inducing for transcription of CYP1A1 mRNA, a commonly used marker for activation of the AHR. Lowering the amount of available cofactor slightly increased the EC50 for the transcriptional response without changing the efficacy or maximal response. Further reduction in the amount of cofactor reduced the efficacy and produced non-monotonic dose-response curves (NMDRCs) at higher ligand concentrations. The shapes of these NMDRCs were reminiscent of the phenomenon of squelching. Resource limitations for transcriptional machinery are becoming apparent in eukaryotic cells. Within single cells, nuclear receptor-mediated gene expression appears to be a stochastic process; however, intercellular communication and other aspects of tissue coordination may represent a compensatory process to maintain an organism’s ability to respond on a phenotypic level to various stimuli within an inconstant environment.